Contact Us | Site Map | SEARCH
 
About HDNEvolution of TreatmentRh-SensitizationAbout RhophylacThe Rhophylac PromiseProfessional ResourcesOrdering and ReimbursementPatient EducationRequest More InformationImportant Safety InformationPrescribing Information


Rh-sensitization

Fetomaternal hemorrhage (FMH), which can occur during pregnancy or delivery, triggers the Rh-negative mother's immune system to develop antibodies against the antigens in her baby's Rh-positive blood. This is called Rh-sensitization or alloimmunization. While this is the most common cause for Rh-sensitization, there are other ways in which sensitization can occur. For instance, Rh-sensitization occurs when someone with Rh-negative blood receives a transfusion of Rh-positive blood or blood components, such as platelets.

While the placenta-cell layer (trophoblast) usually prevents the fetus's blood from entering the mother's bloodstream, certain conditions can create FMH. The resulting Rh-sensitization can occur during any of these events:

  • Delivery
  • Miscarriage
  • Amniocentesis
  • Chorionic villus sampling
  • Placental abruption
  • Manual extraction of placenta
  • External version
  • Childbirth
  • Abortion

Typically, only a small number of antibodies are produced in the first pregnancy. During delivery, however, the mother's immune system becomes sensitized to the Rh factor. In subsequent pregnancies, the mother produces a greater number of antibodies, which cross the placenta to destroy the fetal red blood cells and create significant health risks for the baby. With each subsequent Rh-positive pregnancy, the mother's antibody reaction is faster, with potentially more severe consequences.

The mother needs to receive anti-D IgG treatment during the first pregnancy and immediately following delivery to thwart the danger that can occur with future pregnancies with an Rh-positive fetus.

  • Rh-negative mothers have a 1%–2% risk of being sensitized during the last trimester of pregnancy
    •      —At delivery, the Rh-negative mother has a 10%–15% risk of Rh-sensitization
  • An Rh-negative mother has about a 60% chance of having an Rh-positive baby if the father is Rh-positive

Important Safety Information

Rhophylac® is indicated for suppression of rhesus (Rh) isoimmunization in:

  • Pregnancy and obstetric conditions in non-sensitized, Rho(D)-negative women with an Rh-incompatible pregnancy, including routine antepartum and postpartum Rh prophylaxis and Rh prophylaxis in cases of obstetric complications, invasive procedures during pregnancy, or obstetric manipulative procedures.
  • Incompatible transfusions in Rho(D)-negative individuals transfused with blood components containing Rho(D)-positive red blood cells.

For suppression of Rh isoimmunization, Rhophylac® can be administered IM or IV.

Rhophylac® is indicated to raise platelet counts in Rho(D)-positive, non-splenectomized adult patients with chronic immune thrombocytopenic purpura (ITP). For the treatment of ITP, Rhophylac® must be administered IV.

Rhophylac® is contraindicated in individuals with known anaphylactic or severe systemic reaction to human immune globulin products.

Allergic or hypersensitivity reactions may occur with Rhophylac®; early signs of hypersensitivity include generalized urticaria, chest tightness, wheezing, hypotension, and anaphylaxis. Individuals with selective IgA deficiency can develop antibodies to IgA and may develop severe hypersensitivity and anaphylactic reactions. For these individuals, weigh the expected benefits of treatment against the potential risks.

Rhophylac® is derived from human plasma. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

Suppression of Rh Isoimmunization: For postpartum use following an Rh-incompatible pregnancy, Rhophylac® should not be given to the newborn infant.

The most common adverse reactions in the suppression of Rh isoimmunization with Rhophylac® are nausea, dizziness, headache, injection-site pain, and malaise.

Immune Thrombocytopenic Purpura: The most serious adverse reactions in patients receiving Rho(D) immune globulin have been observed in the treatment of ITP. ITP patients being treated with Rhophylac® should be monitored for signs and symptoms of intravascular hemolysis, including back pain, shaking chills, fever, and hemoglobinuria. Potentially serious complications of intravascular hemolysis include clinically compromising anemia, acute renal insufficiency, and, very rarely, disseminated intravascular coagulation, and death.

The most common adverse reactions observed in the treatment of ITP are chills, pyrexia/increased body temperature, and headache. Mild extravascular hemolysis has also been observed. In patients with preexisting anemia, weigh the benefits of Rhophylac® against the potential risk of increasing the severity of the anemia.

Please see full prescribing information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.